SWA
REGN icon

Stratos Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Stratos Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.72M Buy
8,695
+222
+3% +$170K 0.41% 61
2025
Q4 		$6.54M Buy
8,473
+481
+6% +$327K 0.32% 84
2025
Q3 		$4.49M Sell
7,992
-52
-0.6% -$29.4K 0.22% 114
2025
Q2 		$4.22M Sell
8,044
-183
-2% -$102K 0.22% 114
2025
Q1 		$5.22M Sell
8,227
-354
-4% -$243K 0.29% 88
2024
Q4 		$6.11M Sell
8,581
-67
-0.8% -$56.2K 0.29% 82
2024
Q3 		$9.09M Sell
8,648
-30
-0.3% -$33.4K 0.42% 59
2024
Q2 		$9.12M Buy
8,678
+213
+3% +$206K 0.45% 53
2024
Q1 		$8.15M Buy
8,465
+156
+2% +$148K 0.48% 50
2023
Q4 		$7.3M Hold
8,309
– – 0.42% 51
2023
Q3 		$6.84M Buy
8,309
+266
+3% +$209K 0.45% 45
2023
Q2 		$5.78M Buy
8,043
+180
+2% +$139K 0.41% 59
2023
Q1 		$6.46M Buy
7,863
+800
+11% +$603K 0.5% 39
2022
Q4 		$5.1M Buy
7,063
+4,781
+210% +$3.53M 0.42% 57
2022
Q3 		$1.57M Buy
2,282
+322
+16% +$203K 0.17% 182
2022
Q2 		$1.16M Buy
1,960
+725
+59% +$471K 0.11% 245
2022
Q1 		$863K Sell
1,235
-759
-38% -$480K 0.07% 294
2021
Q4 		$1.26M Buy
1,994
+325
+19% +$200K 0.09% 251
2021
Q3 		$1.01M Buy
+1,669
New +$1.04M 0.09% 253
2021
Q2 		– Sell
-576
Closed -$273K – 550
2021
Q1 		$273K Buy
+576
New +$280K 0.03% 415

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Stratos Wealth Advisors's REGN Position: Q1 2026 in Review

Stratos Wealth Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 2.6% in Q1 2026, buying an estimated $170K and bringing the position to 8,695 shares worth $6.72M. The position accounts for 0.41% of the portfolio, ranked #61.

Stratos Wealth Advisors first reported a position in REGN in Q1 2021 and has held it in 20 quarters since. The position peaked at $9.12M in Q2 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Stratos Wealth Advisors held 8,695 shares of Regeneron Pharmaceuticals worth $6.72M as of Q1 2026.
  • Stratos Wealth Advisors bought 222 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $170K.
  • Regeneron Pharmaceuticals made up 0.41% of Stratos Wealth Advisors's portfolio in Q1 2026, its #61 holding.
  • Stratos Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 20 quarters since.
  • Stratos Wealth Advisors's Regeneron Pharmaceuticals position peaked at $9.12M in Q2 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Stratos Wealth Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.